Rigel Pharmaceuticals
RIGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$564.13M
Close$
$-31.28
203.2% downside
Current Fair Value
203.2% downsideOvervalued by 203.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $564.13 Million |
|---|---|
| Enterprise Value | $585.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.4 |
| Beta | 1.2 |
| Outstanding Shares | 18,412,000 |
Return
| Return on Equity | 91.08% |
|---|---|
| Return on Assets | 72.18% |
| Return on Invested Capital | 29.72% |
Valuation & Multiples
| P/E Ratio | 1.54 |
|---|---|
| PEG | -6.32 |
| Price to Sales | 1.89 |
| Price to Book Ratio | 1.44 |
| Enterprise Value to Revenue | 1.95 |
| Enterprise Value to EBIT | 4.74 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$0.74
Average shareholder expectationRevenue Estimate
$62.40 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$54.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7432▲ 50.35% |
|---|---|
| Total Calls | 70,100▼ 59.22% |
| Total Puts | 52,100▲ 26.46% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.33%▼ 0.90% |
|---|---|
| Total Invested | $429.62M▼ 37.62% |
| Investors Holding | 153▼ 38.00% |
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez